vs
Prestige Consumer Healthcare Inc.（PBH）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Prestige Consumer Healthcare Inc.的1.3倍（$359.3M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs -2.5%，领先19.0%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.7% vs -2.4%），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（12.4% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
PBH vs PCOR — 直观对比
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $359.3M |
| 净利润 | $46.7M | $-9.1M |
| 毛利率 | 55.5% | 80.1% |
| 营业利润率 | 29.1% | 15.5% |
| 净利率 | 16.5% | -2.5% |
| 营收同比 | -2.4% | 15.7% |
| 净利润同比 | -23.5% | 72.4% |
| 每股收益（稀释后） | $0.97 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $359.3M | ||
| Q4 25 | $283.4M | $349.1M | ||
| Q3 25 | $274.1M | $338.9M | ||
| Q2 25 | $249.5M | $323.9M | ||
| Q1 25 | $296.5M | $310.6M | ||
| Q4 24 | $290.3M | $302.0M | ||
| Q3 24 | $283.8M | $295.9M | ||
| Q2 24 | $267.1M | $284.3M |
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $46.7M | $-37.6M | ||
| Q3 25 | $42.2M | $-9.1M | ||
| Q2 25 | $47.5M | $-21.1M | ||
| Q1 25 | $50.1M | $-33.0M | ||
| Q4 24 | $61.0M | $-62.3M | ||
| Q3 24 | $54.4M | $-26.4M | ||
| Q2 24 | $49.1M | $-6.3M |
| Q1 26 | — | 80.1% | ||
| Q4 25 | 55.5% | 80.1% | ||
| Q3 25 | 55.3% | 79.7% | ||
| Q2 25 | 56.2% | 79.1% | ||
| Q1 25 | 57.3% | 79.1% | ||
| Q4 24 | 55.5% | 81.2% | ||
| Q3 24 | 55.5% | 81.4% | ||
| Q2 24 | 54.7% | 83.1% |
| Q1 26 | — | 15.5% | ||
| Q4 25 | 29.1% | -12.3% | ||
| Q3 25 | 29.1% | -4.4% | ||
| Q2 25 | 28.8% | -9.3% | ||
| Q1 25 | 29.8% | -11.7% | ||
| Q4 24 | 31.7% | -21.9% | ||
| Q3 24 | 29.7% | -12.3% | ||
| Q2 24 | 27.0% | -5.2% |
| Q1 26 | — | -2.5% | ||
| Q4 25 | 16.5% | -10.8% | ||
| Q3 25 | 15.4% | -2.7% | ||
| Q2 25 | 19.0% | -6.5% | ||
| Q1 25 | 16.9% | -10.6% | ||
| Q4 24 | 21.0% | -20.6% | ||
| Q3 24 | 19.2% | -8.9% | ||
| Q2 24 | 18.4% | -2.2% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.97 | $-0.25 | ||
| Q3 25 | $0.86 | $-0.06 | ||
| Q2 25 | $0.95 | $-0.14 | ||
| Q1 25 | $1.00 | $-0.22 | ||
| Q4 24 | $1.22 | $-0.42 | ||
| Q3 24 | $1.09 | $-0.18 | ||
| Q2 24 | $0.98 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $386.0M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $1.2B |
| 总资产 | $3.5B | $2.1B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $386.0M | ||
| Q4 25 | $62.4M | $768.5M | ||
| Q3 25 | $119.1M | $684.0M | ||
| Q2 25 | $139.5M | $620.9M | ||
| Q1 25 | $97.9M | $566.7M | ||
| Q4 24 | $50.9M | $775.4M | ||
| Q3 24 | $51.5M | $756.9M | ||
| Q2 24 | $34.3M | $735.4M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.3B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.8B | $1.2B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $1.7B | $1.3B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $3.5B | $2.2B | ||
| Q3 25 | $3.4B | $2.1B | ||
| Q2 25 | $3.4B | $2.0B | ||
| Q1 25 | $3.4B | $1.9B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.3B | $2.0B | ||
| Q2 24 | $3.3B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $76.8M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $76.8M | ||
| Q4 25 | $78.3M | $114.9M | ||
| Q3 25 | $57.5M | $88.5M | ||
| Q2 25 | $79.0M | $30.8M | ||
| Q1 25 | $61.8M | $66.0M | ||
| Q4 24 | $65.1M | $29.1M | ||
| Q3 24 | $69.8M | $39.3M | ||
| Q2 24 | $54.8M | $58.7M |
| Q1 26 | — | — | ||
| Q4 25 | $75.3M | $109.2M | ||
| Q3 25 | $55.4M | $83.1M | ||
| Q2 25 | $78.2M | $27.9M | ||
| Q1 25 | $58.4M | $62.0M | ||
| Q4 24 | $63.5M | $17.4M | ||
| Q3 24 | $67.8M | $35.7M | ||
| Q2 24 | $53.6M | $56.8M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 31.3% | ||
| Q3 25 | 20.2% | 24.5% | ||
| Q2 25 | 31.3% | 8.6% | ||
| Q1 25 | 19.7% | 20.0% | ||
| Q4 24 | 21.9% | 5.8% | ||
| Q3 24 | 23.9% | 12.1% | ||
| Q2 24 | 20.1% | 20.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 1.6% | ||
| Q3 25 | 0.8% | 1.6% | ||
| Q2 25 | 0.3% | 0.9% | ||
| Q1 25 | 1.2% | 1.3% | ||
| Q4 24 | 0.5% | 3.9% | ||
| Q3 24 | 0.7% | 1.2% | ||
| Q2 24 | 0.4% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PCOR
暂无分部数据
